Mars didn’t always look like this. It may have once been covered in oceans. But what if we brought all the Martian water ...

Investing.com -- Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the ...

HSBC upgraded Moderna (MRNA) to Hold from Reduce with a $58 price target Don't Miss our Black Friday Offers:Discover the latest stocks ...

Last week, some large European and U.S. vaccine maker stocks fell in reaction to Robert F. Kennedy Jr.’s nomination to lead ...

On Thursday, Moderna Inc (MRNA) stock saw a decline, ending the day at $39.77 which represents a decrease of $-2.37 or -5.62% from the prior close of $42.14. The stock opened at $42.05 and touched a ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $84.0, a ...

Short interest for healthcare stocks in S&P 500 stayed flat in October vs. September, while Moderna continued to be most shorted stock of the month. The average short interest for S&P 500 Health ...

On Friday, Moderna Inc (MRNA) stock saw a decline, ending the day at $46.83 which represents a decrease of $-3.45 or -6.86% from the prior close of $50.28. The stock opened at $50.42 and touched a low ...

This time, we have GSK (GSK) "GSK" filing a lawsuit against Moderna (NASDAQ:MRNA) accusing them of patent infringement on their lipid nanoparticle (LNP) technology, which is used in mRNA therapeutics.

HSBC’s stock has seen a notable rise, fueled by its bold restructuring efforts and solid third-quarter performance, which have positioned the bank for continued growth. With these strategic ...

HSBC analyst Yifeng Liu upgraded Moderna (MRNA) to Buy from Hold with a price target of $58, down from $82. The recent share price weakness ...